Insider · CIK 0001774478
Christopher Viehbacher
Files at BIIB (BIOGEN INC.), BRVE (Braveheart Bio, Inc.). First filing Aug 7, 2026, latest Aug 7, 2026.
In brief
Christopher Viehbacher files SEC Form 4 as CEO, president and director at BRVE (Braveheart Bio, Inc.), and also at BIIB (BIOGEN INC.). Since Aug 7, 2026, Christopher Viehbacher has reported 1 open-market buy worth $1.5M and 0 open-market sells worth $0, the latest filed on Aug 7, 2026.
A track record needs three past buys with six months of prices behind them; Christopher Viehbacher has 0, so none is measured yet.
The newest scored trade: bought $1.5M of BRVE on Aug 7, 2026, filed Aug 7, 2026, scored 58 (moderate). In the last 12 months: 1 buy worth $1.5M and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
BRVE: Braveheart Bio, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 58Moderate | Braveheart Bio, Inc. | $1.5M 83,333 shares | +16% | - |
Transactions
Every row this insider has filed, 17 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | POpen-market purchase Common Stock | +83,333 | $18.00 | $1.5M | 609,519 | Aug 7, 2026 |
| Aug 5, 2026 | BRVE Braveheart Bio, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +30,000 | $0.00 | $0 | 30,000 | Aug 7, 2026 |
| Feb 13, 2026 | BIIB BIOGEN INC. | AGrant or award Restricted Stock Unitderivative | +38,015 | $0.00 | $0 | 38,015 | Feb 17, 2026 |
| Feb 6, 2026 | BIIB BIOGEN INC. | MOption exercise Common Stock | +9,008 | $0.00 | $0 | 25,451 | Feb 10, 2026 |
| Feb 6, 2026 | BIIB BIOGEN INC. | FTax withholding Common Stock | -4,356 | $201.18 | $876k | 21,095 | Feb 10, 2026 |
| Feb 6, 2026 | BIIB BIOGEN INC. | MOption exercise Common Stock | +15,453 | $0.00 | $0 | 36,548 | Feb 10, 2026 |
| Feb 6, 2026 | BIIB BIOGEN INC. | FTax withholding Common Stock | -6,624 | $201.18 | $1.3M | 29,924 | Feb 10, 2026 |
| Feb 6, 2026 | BIIB BIOGEN INC. | MOption exercise Restricted Stock Unitderivative | -9,008 | $0.00 | $0 | 9,009 | Feb 10, 2026 |
| Feb 6, 2026 | BIIB BIOGEN INC. | MOption exercise Restricted Stock Unitderivative | -15,453 | $0.00 | $0 | 30,907 | Feb 10, 2026 |
| Dec 1, 2025 | BIIB BIOGEN INC. | MOption exercise Common Stock | +7,040 | $0.00 | $0 | 19,847 | Dec 3, 2025 |
| Dec 1, 2025 | BIIB BIOGEN INC. | FTax withholding Common Stock | -3,404 | $177.78 | $605k | 16,443 | Dec 3, 2025 |
| Dec 1, 2025 | BIIB BIOGEN INC. | MOption exercise Restricted Stock Unitderivative | -7,040 | $0.00 | $0 | 0 | Dec 3, 2025 |
| Feb 7, 2025 | BIIB BIOGEN INC. | MOption exercise Common Stock | +9,008 | $0.00 | $0 | 16,008 | Feb 10, 2025 |
| Feb 7, 2025 | BIIB BIOGEN INC. | FTax withholding Common Stock | -3,201 | $141.35 | $452k | 12,807 | Feb 10, 2025 |
| Feb 6, 2025 | BIIB BIOGEN INC. | AGrant or award Restricted Stock Unitderivative | +46,360 | $0.00 | $0 | 46,360 | Feb 10, 2025 |
| Feb 7, 2025 | BIIB BIOGEN INC. | MOption exercise Restricted Stock Unitderivative | -9,008 | $0.00 | $0 | 18,017 | Feb 10, 2025 |
| Feb 7, 2024 | BIIB BIOGEN INC. | AGrant or award Restricted Stock Unitderivative | +27,025 | $0.00 | $0 | 27,025 | Feb 9, 2024 |
Questions about Christopher Viehbacher
Answered from the filings on this page, as of the latest one.
Is Christopher Viehbacher buying or selling?
In the last 12 months Christopher Viehbacher reported 1 open-market buy worth $1.5M and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $1.5M of BRVE on Aug 7, 2026. Grants, option exercises and tax withholding are not counted.
How did Christopher Viehbacher's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Christopher Viehbacher has 0.
Where does Christopher Viehbacher file Form 4?
Christopher Viehbacher has filed Form 4 at BRVE (Braveheart Bio, Inc.); BIIB (BIOGEN INC.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.